Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trial

Trial Profile

Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trial

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant thymoma
  • Focus Therapeutic Use
  • Acronyms PRIMER
  • Most Recent Events

    • 13 Apr 2019 As the early termination criterion (less than one responder) was fulfilled during the first stage, the study was deemed futile and was terminated as per results published in the European Journal of Cancer
    • 13 Apr 2019 Results published in the European Journal of Cancer
    • 03 Oct 2017 Status changed from suspended to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top